Ligand screening approach to find potential inhibitors of GP1 from Ebola Virus
Archives of Advances in Biosciences,
Vol. 8 No. 2 (2017),
21 February 2017
,
Page 31-36
https://doi.org/10.22037/jps.v8i2.13549
Abstract
Ebola is one of the members of filoviruses family. It causes severe hemorrhagic with the human mortality rate of 50-90%. In the initial steps of infection, it enters the host cell by Glyco protein1 (GP1). GP1 is a big subunit with the molecular weight of 130 kDa. Its N-terminal domain is responsible for attaching the host cell. In the present study, a database containing 100.000 drug like chemicals which was obtained from Zinc has been screened. The top successive hits were then analyzed regarding Lipinski rules, oral toxicity value and recorded biological properties. Finally, 3 new ligands were introduced as new theoretical inhibitors of Ebola virus entry. Hit #1 (Heptacyclo[18.7.0.02,10.03,8.011,19.012,17.021,26] heptacosa1(20),2(10),3,5,7,11(19),12,14,16,21,23,25-didecaene-9,18,27-trione) indicated the binding affinity of -10.7 kcal/mol with previous biological reports indicating no toxicity on human cell line. Hit#3 (1,1',3,3'-tetraethyl-5'-(4-nitrophenyl)spiro[1,3-diazinane-5,6'-5H-furo[2,3-d]pyrimidine]-2,2',4,4',6 pentone) with the binding affinity of -9.7 kcal/mol theoretically passed pharmacological filters and the toxicity class of 4 theoretically revealed that this hit also can be a potential anti GP1 agent. Moreover, hit#4(10-(Hydroxymethyl)-7,18-dimethoxy-6,17-dimethyl-21-methyl-11.21 diazapentacyclo[11.7.1.02,11.04,9.015,20]henicosa-4(9),6,15(20),17-tetraene-5,8,12,16,19-pentone) also indicated the binding affinity of -9.7 kcal/mol and was matched with Lipinski rules and the toxicity class 4, suggesting that it can be safe in low dose usage. Based on the pharmacological properties, hit #1, 3 and 4 are presented as the new hypothetical drugs against GP1. Moreover, hit#1 has previously been recorded as nontoxic activity on human cell line and makes it an appropriate candidate for further in vitro and in vivo studies.
- Ebola virus
- GP1
- Virtual screening
- Lipinski
- Drug
How to Cite
References
Gomes MFC, Pastore y Piontti A, Rossi L, Chao D, Longini I, Halloran ME, et al. Assessing the International Spreading Risk Associated with the 2014 West African Ebola Outbreak. PLoS Currents. 2014;6:ecurrents.outbreaks.cd818f63d40e24aef769dda7df9e0da5.
Gire SK, Goba A, Andersen KG, Sealfon RS, Park DJ, Kanneh L, et al. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science (New York, NY). 2014;345(6202):1369-72.
Lee JE, Saphire EO. Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it. Current opinion in structural biology. 2009;19(4):408-17.
Harrison SC. Viral membrane fusion. Nature structural & molecular biology. 2008;15(7):690-8.
White JM, Delos SE, Brecher M, Schornberg K. Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. Critical reviews in biochemistry and molecular biology. 2008;43(3):189-219.
Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, Saphire EO. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature. 2008;454(7201):177-82.
Dube D, Brecher MB, Delos SE, Rose SC, Park EW, Schornberg KL, et al. The primed ebolavirus glycoprotein (19-kilodalton GP1,2): sequence and residues critical for host cell binding. Journal of virology. 2009;83(7):2883-91.
Kaletsky RL, Simmons G, Bates P. Proteolysis of the Ebola virus glycoproteins enhances virus binding and infectivity. Journal of virology. 2007;81(24):13378-84.
Schornberg KL, Shoemaker CJ, Dube D, Abshire MY, Delos SE, Bouton AH, et al. Alpha5beta1-integrin controls ebolavirus entry by regulating endosomal cathepsins. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(19):8003-8.
Brindley MA, Hughes L, Ruiz A, McCray PB, Jr., Sanchez A, Sanders DA, et al. Ebola virus glycoprotein 1: identification of residues important for binding and postbinding events. Journal of virology. 2007;81(14):7702-9.
Manicassamy B, Wang J, Jiang H, Rong L. Comprehensive analysis of ebola virus GP1 in viral entry. Journal of virology. 2005;79(8):4793-805.
Mpanju OM, Towner JS, Dover JE, Nichol ST, Wilson CA. Identification of two amino acid residues on Ebola virus glycoprotein 1 critical for cell entry. Virus research. 2006;121(2):205-14.
Ito H, Watanabe S, Sanchez A, Whitt MA, Kawaoka Y. Mutational analysis of the putative fusion domain of Ebola virus glycoprotein. Journal of virology. 1999;73(10):8907-12.
Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science (New York, NY). 2005;308(5728):1643-5.
Hood CL, Abraham J, Boyington JC, Leung K, Kwong PD, Nabel GJ. Biochemical and Structural Characterization of Cathepsin L-Processed Ebola Virus Glycoprotein: Implications for Viral Entry and Immunogenicity. Journal of virology. 2010;84(6):2972-82.
Delos SE, La B, Gilmartin A, White JM. Studies of the “Chain Reversal Regions” of the Avian Sarcoma/Leukosis Virus (ASLV) and Ebolavirus Fusion Proteins: Analogous Residues Are Important, and a His Residue Unique to EnvA Affects the pH Dependence of ASLV Entry. Journal of virology. 2010;84(11):5687-94.
Abazari D, Moghtadaei M, Behvarmanesh A, Ghannadi B, Aghaei M, Behruznia M, et al. Molecular docking based screening of predicted potential inhibitors for VP40 from Ebola virus. Bioinformation. 2015;11(5):243-7.
Roy A, Kucukural A, Zhang Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nature protocols. 2010;5(4):725-38.
Yang J, Yan R, Roy A, Xu D, Poisson J, Zhang Y. The I-TASSER Suite: protein structure and function prediction. Nature methods. 2015;12(1):7-8.
Zhang Y. I-TASSER server for protein 3D structure prediction. BMC bioinformatics. 2008;9:40.
Wiederstein M, Sippl MJ. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic acids research. 2007;35(Web Server issue):W407-W10.
Brylinski M, Skolnick J. A threading-based method (FINDSITE) for ligand-binding site prediction and functional annotation. Proceedings of the National Academy of Sciences. 2008;105(1):129-34.
Skolnick J, Brylinski M. FINDSITE: a combined evolution/structure-based approach to protein function prediction. Briefings in Bioinformatics. 2009;10(4):378-91.
Irwin JJ, Sterling T, Mysinger MM, Bolstad ES, Coleman RG. ZINC: A Free Tool to Discover Chemistry for Biology. Journal of Chemical Information and Modeling. 2012;52(7):1757-68.
Pronk S, Páll S, Schulz R, Larsson P, Bjelkmar P, Apostolov R, et al. GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics. 2013;29(7):845-54.
Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. Methods in molecular biology (Clifton, NJ). 2015;1263:243-50.
Manicassamy B, Wang J, Jiang H, Rong L. Comprehensive Analysis of Ebola Virus GP1 in Viral Entry. Journal of virology. 2005;79(8):4793-805.
Lagorce D, Sperandio O, Baell JB, Miteva MA, Villoutreix BO. FAF-Drugs3: a web server for compound property calculation and chemical library design. Nucleic acids research. 2015;43(W1):W200-7.
Drwal MN, Banerjee P, Dunkel M, Wettig MR, Preissner R. ProTox: a web server for the in silico prediction of rodent oral toxicity. Nucleic acids research. 2014;42(Web Server issue):W53-8.
Vande Burgt NH, Kaletsky RL, Bates P. Requirements within the Ebola Viral Glycoprotein for Tetherin Antagonism. Viruses. 2015;7(10):5587-602.
Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, Saphire EO. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature. 2008;454(7201):177-82.
Brecher M, Schornberg KL, Delos SE, Fusco ML, Saphire EO, White JM. Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion-relevant conformational change. Journal of virology. 2012;86(1):364-72.
- Abstract Viewed: 460 times
- PDF Downloaded: 205 times